Shares of Alphatec Holdings Inc (NASDAQ:ATEC) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 1-year consensus target price of $4.00 for the company and are expecting that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also given Alphatec an industry rank of 145 out of 256 based on the ratings given to related companies.
Several research analysts have recently commented on the company. Zacks Investment Research raised Alphatec from a “sell” rating to a “hold” rating in a research report on Monday, May 13th. HC Wainwright set a $4.00 price target on Alphatec and gave the stock a “buy” rating in a research report on Tuesday, February 26th.
In other Alphatec news, Director Evan Bakst bought 20,566 shares of Alphatec stock in a transaction that occurred on Monday, March 11th. The shares were bought at an average cost of $2.59 per share, with a total value of $53,265.94. Following the transaction, the director now directly owns 726,912 shares of the company’s stock, valued at approximately $1,882,702.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Craig E. Hunsaker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $4.50, for a total value of $225,000.00. The disclosure for this sale can be found here. Insiders own 44.40% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Cerity Partners LLC increased its position in Alphatec by 350.5% during the 1st quarter. Cerity Partners LLC now owns 2,301,983 shares of the medical technology company’s stock valued at $6,100,000 after buying an additional 1,791,023 shares in the last quarter. Vanguard Group Inc increased its position in Alphatec by 57.4% during the 3rd quarter. Vanguard Group Inc now owns 684,865 shares of the medical technology company’s stock valued at $2,308,000 after buying an additional 249,632 shares in the last quarter. Vanguard Group Inc. increased its position in Alphatec by 57.4% during the 3rd quarter. Vanguard Group Inc. now owns 684,865 shares of the medical technology company’s stock valued at $2,308,000 after buying an additional 249,632 shares in the last quarter. Renaissance Technologies LLC increased its position in Alphatec by 20.3% during the 3rd quarter. Renaissance Technologies LLC now owns 583,145 shares of the medical technology company’s stock valued at $1,965,000 after buying an additional 98,500 shares in the last quarter. Finally, Penn Capital Management Co. Inc. acquired a new position in Alphatec during the 1st quarter valued at about $1,261,000. 18.04% of the stock is currently owned by institutional investors.
Shares of ATEC stock traded up $0.07 during mid-day trading on Wednesday, hitting $4.22. The stock had a trading volume of 255,310 shares, compared to its average volume of 442,691. Alphatec has a 12-month low of $1.18 and a 12-month high of $4.79. The stock has a market capitalization of $197.74 million, a price-to-earnings ratio of -7.28 and a beta of 1.52. The company has a current ratio of 2.31, a quick ratio of 1.53 and a debt-to-equity ratio of 4.79.
Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Thursday, May 9th. The medical technology company reported ($0.20) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.20). The firm had revenue of $24.56 million during the quarter, compared to analyst estimates of $24.00 million. Alphatec had a negative return on equity of 156.32% and a negative net margin of 42.16%. Research analysts predict that Alphatec will post -0.65 EPS for the current fiscal year.
Alphatec Company Profile
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Read More: Price to Earnings Ratio (PE), For Valuing Stocks
Get a free copy of the Zacks research report on Alphatec (ATEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.